Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC By Ogkologos - June 25, 2025 567 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline EMA Recommends Extending Indications for Decitabine / Cedazuridine MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Lutetium (177lu) Chloride August 4, 2022 Biweekly Cabazitaxel in Patients 65 Years or Older with mCRPC for... November 7, 2023 How to Clean Your Home When Caring for Someone With Cancer October 7, 2020 EMA Recommends Extending Indications for Durvalumab July 17, 2025 Load more HOT NEWS Workout Wednesdays – Chest Exercises Part 2 A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with... First-Line Pembrolizumab Continues to Show Durable Clinical Benefit After 5 Years... Ventana HER2 Dual ISH Assay, A New Diagnostic Tool From Roche,...
